Asian J. Pharm. Ana. 2011; Vol. 1: Issue 4, Pg 67-70 [AJPAna.] 67 ISSN- 2231–5667 (Print) www.asianpharmaonline.org ISSN- 2231–5675 (Online) 0974-3618 REVIEW ARTICLE An Analytical Approach of Doxofylline: A Review Akhilesh Gupta 1 *, Vimal Yadav 1 , Jaydeep S. Yadav 1 and Swati Rawat 2, 1 Kunwar Haribansh Singh College of Pharmacy, Jaunpur (U.P.) 2 Shri Bhagwan College of Pharmacy, Aurangabad (M.S.) *Corresponding Author E-mail: akhileshgupta81@rediffmail.com ABSTRACT: Doxofylline is chemically designated as 7-(1, 3 dioxolone-2-yl methyl) theophylline. Presence of a dioxolane group in position C-7 differentiates it from theophylline. It is a new antibronchospastic drug recently introduced in therapy with pharmacological properties like theophylline; a potent adenosine receptor antagonist. doxofylline do not affect gastric acid secretion; either invivo or in-vitro; unlike theophylline. The lack of side effects with doxofylline indicates that the drug can be used safely and effectively. Some analytical methods for quantitative determination of doxofylline in pharmaceutical formulations like UV-Spectrophotometry, HPLC and LC-MS are reported. The present review deals with the various analytical methods reported as well as adopted for the estimation of doxofylline. KEYWORDS: Doxofylline, UV, HPLC, LC-MS. INTRODUCTION: Doxofylline is methyl xanthine derivatives 1 ; it is a bronchodilator and plays a direct role in bronchial relaxation of bronchial smooth muscle. Doxofylline by inhibiting the phosphodiesterase within the smooth muscle cells and cause smooth muscle relaxation, thus achieving suppression of asthma. Doxofylline is a novel bronchodilator xanthine that differs from theophylline because the presence of a dioxalane group in position C-7 2 . Like theophylline, mechanism of action of doxofyllines is related to the inhibition of phosphodiesterase activities. However, differently from theophylline, doxofylline appears to have decreased affinities toward adenosine A1 and A2 receptors which may account for the better safety profile of the drug 3 . As per pharmacokinetic parameters it absorbed rapidly. In healthy adults for the first 0.4 g oral, time to peak plasma concentration (Tmax) was 1.22 hours, the peak plasma concentration (Cmax) for a 0.9  g / ml. The materials widely distributed in various organs, with the highest content in the lungs 4 . The phony goods to and from the form of metabolites in urine excretion, for the main metabolite of  - hydroxyethyl theophylline. Received on 09.09.2011 Accepted on 18.10.2011 © Asian Pharma Press All Right Reserved Asian J. Pharm. Ana. 1(4): Oct. - Dec. 2011; Page 67-70 The elimination half-life of the goods (t1 / 2) for 7.42 hours. Eight healthy male volunteers for each of the 0.4 g of oral, twice daily, for seven days, reaching a steady state Cmax (13.00 ± 2.54)  g / ml, Cmin (3.22 ± 1.99)  g / ml, steady Mean plasma concentration of (7.11 ± 1.72)  g / ml. Taking xanthine derivatives may cause nausea, vomiting, abdominal pain, headache, insomnia, irritability, tachycardia, period of contraction, shortness of breath, high blood sugar, and proteinuria. Excessive use will emerge as a serious arrhythmia 5 . ANALYTICAL APPROACH FOR THE DETERMINATION OF DOXOFYLLINE: H R Joshi and coworkers 6 reported two methods for determination of Doxophylline in solid dosage form. The first method was based on UV-Spectrophotometric determination of the drug. It involves absorbance measurement at 274 nm (absorption maxima of Doxophylline) in 0.1 N hydrochloric acid. Calibration curve was linear with the correlation coefficient between 0.99 to 1.0 over a concentration range of 0.20 to 30 µg/ml for the drug. The second method was based on HPLC separation of the drug in reverse phase mode using Hypersil ODS C18 column (250 X 4.6mm). The mobile phase constituted of Buffer: Acetonitrile (80:20) and pH adjusted to 3.0 with dilute orthophosphoric acid was delivered at the flow rate 1.0 ml min-1. Detection was performed at 210 nm. Separation was completed within 7 min. Calibration curve